Can you compare the commonalities and differences between biomarkers of exposure, effect and susceptibility?
Can you describe population approaches to human biomonitoring in Europe and the USA (e.g. COPHES & DEMOCOPHES; CDC National Report)?
Can you recognize the utility of human biomonitoring in epidemiology and risk assessment of chemical exposures?
Can you describe the methods which are (misused for the diagnosis of low level toxin exposure?
Can you discuss purported detoxification treatments such as mineral supplementation, homeopathic single or complex remedies, apheresis and chelation therapy?
Can you interpret the evidence for efficacy of such therapies from well-designed clinical trials?
Can you describe the advantages and disadvantages of the use of biomarkers for evaluation of human exposure to volatile organic compounds, metals, polycyclic organic hydrocarbons, external tobacco smoke and cytostatic drugs in occupational settings and in the general environment?
Can you describe methods for interpretation of results?
Can you list the various factors which can affect the exposure and health effects?
Can you compare the use of biological monitoring and environmental monitoring?
Can you review the epidemiology of occupational and non-occupational lead exposures reported to the UK National Poisons Information System?
Can you outline how to quantify dose–response data for more accurate hazard and exposure assessment?
Can you describe the use of more accurate and sensitive outcome measures for neurotoxicity and renal toxicity?
Can you describe how to use and validate pharmacokinetic-dynamic modelling strategies?
Can you list serum enzymes and proteins undergoing investigation as biomarkers of hepatotoxicity?
Can you describe the potential for toxicogenomics, toxicometabonomics, and toxicoproteomics to generate hepatotoxicity biomarkers?
Can you describe why a panel of hepatic biomarkers might predict toxicity better than a single biomarker?